As we seek to expand the number of rheumatologists and researchers in the United States focusing on spondyloarthritis, the Spondylitis Association of America hopes to encourage new, upcoming rheumatologists to focus on the future of treatment and research in ankylosing spondylitis and related diseases.
To this end, we created the Spondylitis Association of America/Bruckel Early Career Investigator Award, which recognizes outstanding "contributions to the care and understanding of patients with spondyloarthritis." The award winner receives a $20,000 grant from SAA for use in spondylitis research. The award, named in honor of our co-founder Jane Bruckel, is given annually to the early career investigator who shows the most promise to contribute to the understanding or therapy of axial spondyloarthritis.
For more than 30 years, the Spondylitis Association of America has spoken out on behalf of all who suffer from spondylitis. By making a donation to SAA, you will directly contribute to much-needed public awareness efforts, educational outreach programs, research initiatives, treatment advances and the ongoing search for the cure. Add your voice to our mission to be a leader in the quest to cure ankylosing spondylitis and related diseases, and to empower those affected to live life to the fullest. Together, our voice is louder. Together, we make a difference.
Pamela Weiss, MD, MSCE, is a pediatric rheumatologist at Children’s Hospital of Philadelphia (CHOP) whose clinical and research interests are focused on juvenile spondyloarthritis (JSpA).
Dr. Weiss earned an A.B. in Molecular Biology from Princeton University, and her medical degree from Albert Einstein College of Medicine (2002). She completed both her Pediatrics Residency and Rheumatology fellowship training at CHOP. Dr. Weiss was co-principal investigator of the American College of Rheumatology (ACR) JIA Treatment Recommendations Update, as well as a member of the Core Expert Panel for development of the 2014 Clinical Practice Guidelines for Axial Spondyloarthritis, a collaborative undertaking between ACR, SAA, and SPARTAN. Additionally, Dr. Weiss serves on the ACR Pediatric Rheumatology Special Committee. Her commitment to research and improving the care of children with juvenile arthritis is also evident in her roles as vice chair of the Childhood Arthritis & Rheumatology Research Alliance (CARRA) Juvenile Arthritis Research Committee and her recent appointment as Clinical Research Director for the CHOP Division of Rheumatology. She has lectured nationally and internationally on juvenile arthritis and spondyloarthritis.
Dr. Weiss’ research focuses on the pharmacoepidemiology and outcomes of JSpA. JSpA is an umbrella term that also encompasses three categories of juvenile idiopathic arthritis (JIA) -- enthesitis-related arthritis (ERA), juvenile psoriatic arthritis, and undifferentiated arthritis (children who meet criteria for more than one JIA category). Using patient-reported data from the CHOP clinic, she demonstrated that children with ERA have worse function, poorer quality of life, and higher pain intensity than children with other categories of JIA. She confirmed and published these findings using a large national registry of pediatric rheumatic diseases. To address the knowledge gaps of this understudied condition, her efforts are specifically directed to better defining the disease and developing treatment strategies for children that will directly improve both clinical and patient-reported outcomes.
Nigil Haroon, MD, PhD, is a rheumatologist at the University Health Network and an assistant professor of medicine and rheumatology at the University of Toronto. He has a keen interest in ankylosing spondylitis (AS). Specifically, his area of research includes radiographic progression, identifying novel therapeutic targets and understanding the immunology and genetics of AS. He is well published in this area and has been an invited speaker at several international meetings. Dr. Haroon has won several awards, including a CRA young faculty award for both clinical and basic research and, in 2013, the Spondylitis Association of America/Bruckel Early Career Investigator Award.
Dr. Haroon has a well-established translational research program at the University Health Network in Toronto and is renowned for his work in the functional genomics of AS, especially the role of a new gene, ERAP1, which was found to be strongly associated with AS in genome-wide association studies. He has published paradigm-shifting studies in AS, including work on disease modification in AS with tumor necrosis factor (TNF) inhibitors. He published the largest population based study in AS, showing a significantly increased risk of mortality in AS patients after experiencing heart attacks and strokes. As a result of this study, there is now an emphasis on early identification and treatment of traditional cardiovascular risk factors in AS patients.
Lianne Gensler, MD, is a rheumatologist at the University of California, San Francisco (UCSF) Medical Center and is director of the Ankylosing Spondylitis Clinic.
Dr. Gensler earned a medical degree at the University of California, Irvine. She completed an internal medicine residency, chief residency, and rheumatology fellowship at UCSF and then joined the medical staff in rheumatology. Her primary research interest is in studying the disease progression of ankylosing spondylitis and identifying predictors of osteoporosis development in patients with systemic lupus erythematosus. She is an assistant clinical professor of medicine at UCSF.
Dr. Gensler states, “Though we believe that ankylosing spondylitis is strongly rooted in genetics, what we are less clear on is how we can slow down its progression. Through our research, we have been able to show that smoking is a risk for progression, doubling the odds. We have also shown for the first time that patients who use the biologic agents - (TNF inhibitors) - have a more than 50 percent reduction in the risk of progression. It is not clear that everyone needs these drugs, as some patients may never progress, and some patients may be able to mitigate this progression by other modalities. I am thrilled to be able to continue to work on these ideas and help move the field forward.”
Judith Anne Smith, MD, graduated summa cum laude from Yale University. She then completed her MD/PhD program at the University of Chicago NIH Medical Scientist Training Program. Her graduate work in immunology was performed under the guidance of Dr. Jeffrey Bluestone. After completing her medical degree, she completed her pediatrics residency and pediatric rheumatology fellowship training at Cincinnati Children’s Hospital. Her fellowship training, under Dr. Robert Colbert, inspired her to pursue research in the pathogenesis of ankylosing spondylitis (AS) and related conditions. She joined the faculty as an assistant professor in pediatrics at the University of Wisconsin in Madison, where she continues to care for pediatric patients in the Pediatric Rheumatology Clinic and leads an active research program. Dr. Smith’s research goal remains to elucidate the fundamental processes that drive the evolution of ankylosing spondylitis in hopes of ultimately leading to more rational therapeutic development.
The macrophage is an important cell in the inflammatory response. Macrophages and other cells in the immune system produce cytokines such as tumor necrosis factor (TNF) when they are activated. Inhibition of these cytokines can be an effective therapeutic strategy in AS.
Dr. Smith and her colleagues at the University of Wisconsin showed that, compared to healthy controls, macrophages from patients with ankylosing spondylitis make more cytokines when stimulated with a bacterial product. The cytokine, IL-23, was especially increased. Pharmaceutical companies are actively testing inhibitors of IL-23 or inhibitors that target cytokines induced by IL-23 as potential treatment for AS.
PO Box 5872
Sherman Oaks, CA 91413
(800) 777-8189 U.S. only
or (818) 892-1616